Clinical trials
Malignancy clinical trials
Below are recruiting malignancy clinical trials, each written for real people, not researchers. We’re tracking 1,586 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04186520RecruitingPhase 1/Phase 2
CAR T-cell treatment for hard-to-treat B-cell lymphomas
This trial studies a type of lab-made immune cell therapy (CAR T) using cells called CAR-20/19-T. It is for adults with relapsed or refractory B-cell cancers, aiming to reduce or eliminate lymphoma in people whose disease has come back or not responded to standard treatments.
Milwaukee, WisconsinAges 18–80 - NCT04185935Recruiting
Genetic study of cancer in patients and their families
This study looks at DNA patterns in families where cancer may run in families, to better understand inherited (passed-down) cancer risk. You may be able to help even if you’re not sure whether your cancer is genetic—your family history and, if needed, medical records or tumor samples can be used.
Phoenix, ArizonaAges Any age - NCT04187703RecruitingEarly Phase 1
Testing azacitidine and decitabine for bone marrow cancers
This early-phase study tests whether combining two “epigenetic” medicines—azacitidine and decitabine—can improve outcomes for certain bone marrow cancers. It may help if you have a type of myelodysplastic syndrome (MDS) or MDS/MPN overlap that is expected to be sensitive to these medicines.
Cleveland, OhioAges 18 years+ - NCT04195633RecruitingPhase 2
Haploidentical donor stem cell transplant to treat blood cancers
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
Seattle, WashingtonAges 6 months+ - NCT04197414Recruiting
Urology DNA registry to personalize cancer care
This study builds a urology cancer “DNA registry” by analyzing circulating tumor DNA found in the blood. Your information and permission help researchers better personalize treatment for cancers like prostate, kidney, bladder, and ureter cancer.
SeoulAges 20 years+ - NCT04221893Recruiting
Radiation for tumors that keep growing despite immunotherapy
This study tests whether targeted radiation can help people with metastatic gastrointestinal cancers whose cancer is still getting worse on immunotherapy. It focuses on treating a small number of spots that are progressing while keeping other spots that are safer to leave alone.
San Francisco, CaliforniaAges 18 years+ - NCT04227015RecruitingEarly Phase 1
Study of a CD19 CAR T-cell treatment for relapsed leukemia
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
Hangzhou, ZhejiangAges 3–70 - NCT04235777RecruitingPhase 1
Immunotherapy plus radiation for metastatic non-prostate genitourinary cancers
This Phase 1 study tests a new immunotherapy drug (bintrafusp alfa) alone or combined with another investigational antibody drug, plus stereotactic body radiation (SBRT), to treat metastatic genitourinary cancers that are not prostate cancer. It aims to find the safest dose and to see whether the combination can shrink tumors.
Bethesda, MarylandAges 18–120 - NCT04263857Recruiting
Register of Stem Cell Transplant Patients
This study creates a record of people who are eligible to receive a stem cell (blood-forming cell) transplant. It helps researchers learn about transplant patients and outcomes over time.
MunichAges 18 years+ - NCT04275557Recruiting
Using scan and blood data to judge pancreatic cyst risk
This study looks at how medical images and lab samples can predict which pancreatic cysts or tumors are more likely to be dangerous. If you are being evaluated for a pancreatic problem and haven’t started pancreas treatment, your scans and samples may help researchers improve risk prediction.
Lakewood Rch, FloridaAges 18 years+ - NCT04278287RecruitingPhase 1/Phase 2
Chemoradiation study for unresectable esophageal cancer
This Phase 1/2 trial tests a treatment plan using chemotherapy plus radiation for esophageal squamous cell cancer that cannot be removed with surgery. It may help shrink or control the cancer and guide safer dosing, but it’s only for people with specific tumor stage, health status, and blood test results.
Anyang, HenanAges 18–75 - NCT04290000Recruiting
Share samples after CAR-T treatment at Montpellier hospital
This study collects and stores biological samples from people who have been treated with CAR-T cells at the University Hospital of Montpellier. Your samples can help researchers learn more about treatment effects and safety.
MontpellierAges 18 years+ - NCT04299191RecruitingPhase 1/Phase 2
LAM561 for children with advanced brain or solid tumors
This Phase 1/2 study tests a medicine called LAM561 in children whose cancer is advanced and not responding to standard treatment. The goal is to see if the drug is safe and can shrink or control tumors in this setting.
Little Rock, ArkansasAges Up to 18 years - NCT04305691RecruitingPhase 2
Ixazomib for skin Kaposi sarcoma in people with HIV
This trial studies ixazomib (a targeted anti-cancer medicine) to treat cutaneous (skin) Kaposi sarcoma. It aims to shrink measurable skin lesions and improve symptoms, especially in people living with HIV.
San Diego, CaliforniaAges 18 years+ - NCT04308330RecruitingPhase 1
Vorinostat plus chemotherapy for advanced tumors in brain
This Phase 1 trial studies how safe and tolerable vorinostat is when combined with chemotherapy for cancers that have come back or are hard to treat, including tumors in the brain or spinal cord. It may help doctors find a better way to treat advanced solid tumors and CNS (brain/spinal cord) cancers.
Valhalla, New YorkAges 1–30 - NCT04400539RecruitingPhase 2
Nivolumab plus 5-ALA light treatment for pleural mesothelioma
This Phase 2 study tests whether adding nivolumab (an immunotherapy) to a one-time “light-based” treatment during a lung procedure can control malignant pleural mesothelioma that can’t be surgically removed. You may be eligible if your cancer has come back or progressed after prior platinum chemotherapy, and if your tumor is reachable for the light treatment during thoracoscopy.
LilleAges 18 years+ - NCT04453072Recruiting
iPhone weight-loss app for teens and young adults after transplant
This study tests whether an iPhone weight-management app can help adolescents and young adults lose weight after a stem cell transplant. If you qualify, you’ll use the app and the team will track changes in weight.
Los Angeles, CaliforniaAges 13–30 - NCT04475705RecruitingPhase 4
Propofol or sevoflurane for anesthesia in child tumor surgery
This trial compares two types of anesthesia medicine—propofol versus sevoflurane—during planned surgery to remove a solid tumor. It aims to find which option is safer and works better for children having curative tumor surgery.
Hong KongAges 6 months–18 years - NCT04495790Recruiting
Cancer patient study to track health outcomes
This is an observational study that follows people with cancer to better understand outcomes over time. You may be asked to complete questionnaires and share information from your visits (in person or by video only if you meet their rules).
Seattle, WashingtonAges Any age - NCT04501120RecruitingPhase 1/Phase 2
Study drug for relapsed AML and related blood cancers
This early-phase trial tests lisaftoclax, alone or with other medicines, in people whose acute leukemia has returned or did not respond to prior treatment. It aims to find out how well the treatment works and how safe it is, especially for patients who may not be able to take standard chemotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04511039RecruitingPhase 1
New targeted pill combo for advanced colon or stomach cancers
This Phase 1 trial tests a combination of oral (swallowed) drugs—trifluridine/tipiracil plus talazoparib—in people with advanced (locally advanced or metastatic) colorectal or gastroesophageal adenocarcinoma. It’s designed to see how well the treatment can control cancer and to better understand side effects and dosing.
Buffalo, New YorkAges 18 years+ - NCT04511013RecruitingPhase 2
Trial for BRAF-mutant melanoma spread to the brain
This Phase 2 study tests whether a 3-drug plan (encorafenib + binimetinib + nivolumab) works better than ipilimumab + nivolumab for melanoma that has spread to the brain. If you qualify, you’ll get either treatment and have frequent brain scans to track how well it controls the tumors.
Birmingham, AlabamaAges 18 years+ - NCT04515836RecruitingPhase 2
Olaparib for HRD malignant mesothelioma after platinum chemotherapy
This trial tests whether olaparib (a cancer medicine) can help control malignant mesothelioma that has specific DNA changes. You must have already had platinum chemotherapy and your cancer must be “platinum-sensitive,” plus your tumor (or family/genetic cells) must show certain gene problems.
Chicago, IllinoisAges 18 years+ - NCT04528355Recruiting
Study of hospital data after stem cell transplant for non-cancer illness
This study collects medical information from people with certain non-cancer conditions who receive a stem cell transplant. It may help doctors better understand transplant outcomes and care, since the study focuses on data collection rather than adding new treatment.
Pittsburgh, PennsylvaniaAges 2 months–60 years
Hear when a new Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for malignancy?
- Yes. Clin2 currently lists 1,586 recruiting malignancy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a malignancy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a malignancy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.